Business Standard

Remdesivir reduces hospital stay, doesn't show benefit in mortality: AIIMS

AIIMS Director Dr Randeep Guleria explained the ways in which Covid-19 patients are being treated

coronavirus
Premium

(FILE PIC) Health workers collect swab samples from people for Covid-19 tests in New Delhi | Photo: PTI

ANI New Delhi
Remdesivir helps decrease hospital stay but the benefits don't reflect as far as death or mortality is concerned, All India Institute of Medical Sciences (AIIMS) New Delhi Director Dr Randeep Guleria said on Friday.

"There is no definite anti-viral drug which has been proved as far as Covid-19 is concerned. A lot of research is going on. There are some anti-viral drugs which are being used, one of them is 'Remdesivir' that is being made by a company from the US. Data suggests that it helps to decrease hospital stay but it doesn't show benefit as far as death or

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 13 2020 | 12:28 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com